Loading
Cardiovascular Disease and Adiposity / Hormonal Regulation and Hypertension / Diabetes Treatment and Management · Review
International Journal of Science and Research · August 12, 2026
A consensus or society position rather than new primary data.
This narrative review synthesises evidence on cardiometabolic risk factor treatment in adults with cardiovascular-kidney-metabolic syndrome, endorsing a risk-based architecture centred on lifestyle, SGLT2 inhibitors, GLP-1 therapies, RAS blockade with finerenone for albuminuric CKD, and aggressive lipid and blood-pressure control. It emphasises that in India, the principal need is not new efficacy evidence but closure of a substantial implementation gap: statin and antiplatelet use remain below 2% in high-risk individuals, and LDL-cholesterol goals are met in only ~25% of patients with established coronary disease despite statin therapy.
Narrative review. Adults with cardiovascular-kidney-metabolic syndrome across CKM stages 0–4; emphasis on epidemiology and treatment-response data relevant to Indian practice. Intervention: Lifestyle and weight management; SGLT2 inhibitors; GLP-1-based therapies; RAS blockade; non-steroidal mineralocorticoid receptor antagonist (finerenone); statin and antiplatelet therapy; blood-pressure control. Multi-national; Indian real-world and registry data (ICMR-INDIAB) explicitly included.
Large population cohorts confirm graded, accelerating rise in all-cause and cardiovascular mortality across CKM stages 0–4 Indian nationally representative data (ICMR-INDIAB) document very high underlying burden of component risk factors Statin and antiplatelet use documented below 2% in individuals with major cardiovascular risk factor in Indian real-world settings
Large population cohorts confirm graded, accelerating rise in all-cause and cardiovascular mortality across CKM stages 0–4
Practitioners should adopt the foundational, risk-based treatment architecture outlined (lifestyle, cardioprotective antihyperglycaemic agents, RAS blockade with finerenone, lipid and BP control) with awareness of distinct safety signals requiring active monitoring. In Indian settings, the priority is implementing existing guideline recommendations rather than awaiting new efficacy data.
A narrative review synthesising trial evidence and real-world observational data to support a multi-society clinical practice framework for CKM syndrome management, intended to guide physician practice rather than report original research findings.
As stated by the source record.
Quoted from the source exactly as published.
Practitioners should adopt the foundational, risk-based treatment architecture outlined (lifestyle, cardioprotective antihyperglycaemic agents, RAS blockade with finerenone, lipid and BP control) with awareness of distinct safety signals requiring active monitoring. In Indian settings, the priority is implementing existing guideline recommendations rather than awaiting new efficacy data.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background: Cardiovascular-kidney-metabolic (CKM) syndrome describes the mechanistic and clinical overlap between excess or dysfunctional adiposity, metabolic risk factors, chronic kidney disease (CKD), and cardiovascular disease (CVD). The American Heart Association formally defined and staged it (Stage 0 through Stage 4) in 2023,?,? and the AHA, American College of Cardiology (ACC), American Diabetes Association (ADA), and American Society of Nephrology (ASN) translated that framework into a full multi-society clinical practice guideline in 2026.? Objective: To synthesise published epidemiological, randomised-trial, and real-world observational evidence on the treatment of cardiometabolic risk factors in adults with CKM syndrome - with attention to data relevant to Indian clinical practice - and to summarise the safety and tolerability profile of guideline-recommended agents alongside their efficacy. Evidence synthesis: Large population cohorts confirm a graded, accelerating rise in all-cause and cardiovascular mortality across CKM stages, while nationally representative Indian data (ICMR-INDIAB) document a very high underlying burden of the component risk factors. Contemporary trial evidence supports a foundational, risk-based treatment architecture built on lifestyle and weight management, cardioprotective antihyperglycaemic therapy (SGLT2 inhibitors and GLP-1-based therapies), renin-angiotensin-system (RAS) blockade with a non-steroidal mineralocorticoid receptor antagonist for albuminuric CKD, and aggressive lipid and blood-pressure control. Each pillar carries a distinct safety signal - GI intolerance with GLP-1-based agents, genital mycotic infection and rare euglycaemic ketoacidosis with SGLT2 inhibitors, hyperkalaemia with finerenone - that is clinically manageable but needs active monitoring, not passive prescribing. Observational findings: Indian real-world data repeatedly document a wide gap between guideline recommendation and everyday prescribing - statin and antiplatelet use below 2% in individuals with a major cardiovascular risk factor, and LDLcholesterol goal attainment in only about one in four patients with established coronary disease, despite statin therapy. Conclusion: Closing the treatment-implementation gap, not generating further efficacy data, is the principal unmet need in CKM care in India.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.